Edwards Lifesciences (NYSE:EW) 2025 Investor Day December 04, 2025 08:30 AM ET Company ParticipantsCarrie Reddick - Director of Interventional Cardiology and Structural HeartTodd Brinton - Chief Scientific Officer and Corporate VP of Advanced Innovation and TechnologyDavid Roman - Managing Director of Global Investment ResearchScott Ullem - Corporate VP and CFOMichael Mack - Medical Director of Cardiovascular SurgeryNone - Unkown Speaker 1Diane Gomez-Thinnes - Corporate VP of Implantable Heart Failure Manag ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $3.3 billion, an increase of 5.3% year-over-year, driven by organic growth of 2.1% and net acquisitions of 3.7%, partially offset by foreign currency translation of 0.5% [17] - Adjusted earnings per share (EPS) was $3.84, up 4% year-over-year [19] - Operating income for the quarter was $326 million, or 9.7% of revenue, with adjusted operating income at $469 million, or 14% of revenue [17][18] Business Line Data and Key Metrics Changes - Diagnostics Laboratories revenue was $2.6 billion, a 6% increase year-over-year, with organic growth of 1.6% and net acquisitions contributing 4.7% [21] - Biopharma Laboratory Services (BLS) revenue was $721 million, a 1.5% increase year-over-year, with organic revenue growth of 2.6% [23] - Diagnostics adjusted operating income was $428 million, or 16.3% of revenue, compared to $418 million, or 16.9% of revenue last year [22] Market Data and Key Metrics Changes - The book-to-bill ratio for BLS was strong at 1.13 for the quarter, with a trailing twelve-month ratio of 1.07 [24] - Total volume in Diagnostics increased by 3% year-over-year, with organic volume contributing 0.9% [21] Company Strategy and Development Direction - The company aims to be a partner of choice for health systems and regional laboratories, focusing on launching new tests in high-growth therapeutic areas [10] - Strategic collaborations and acquisitions, such as with Inspira Health and BioReference Health, are expected to enhance growth and expand market presence [10][11] - The company is focused on four strategic areas: oncology, women's health, autoimmune disease, and neurology, which are projected to grow faster than other therapeutic areas [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the dynamic macroeconomic and regulatory landscape, reaffirming revenue and free cash flow guidance while increasing the midpoint of EPS guidance by $0.05 per share [9][26] - The company anticipates continued margin expansion across all segments for the full year [28] - Management is closely monitoring regulatory developments and tariff impacts, with contingency plans in place [8][40] Other Important Information - The company reported a free cash flow use of $108 million for the quarter, with expectations of $1.1 billion to $1.25 billion for the full year [20] - The company has a strong business development pipeline and is committed to operational efficiencies through technology [15][11] Q&A Session Summary Question: Variability in BLS segment guidance - Management indicated that the BLS business had about 3% growth overall, with continued strength in the book-to-bill ratio, allowing for flexibility in guidance [34][35] Question: Tariffs impact on guidance - Management confirmed that tariffs are embedded in guidance, with a focus on maintaining operational resilience through flexible supply chains [40][43] Question: Expectations on organic growth in Diagnostics - Management expects about half of the growth to come from organic sources, with adjustments for weather and revenue days indicating a stronger underlying trend [48][50] Question: Impact of regulatory changes on animal testing - Management noted that animal testing currently represents 10-15% of BLS revenue, with no significant impact expected this year from potential regulatory changes [71][72] Question: Invitae's performance and integration - Management expressed confidence in Invitae's integration, expecting it to be slightly accretive for the full year, with revenue growth projected over 10% [80][81] Question: Lab M&A environment - Management reported a strong pipeline for acquisitions, with increased outreach from potential partners due to macroeconomic pressures [86][87]